Hikma signs exclusive licence agreement with Azanta for Nimoral

AMMAN – Amman-based Hikma Pharmaceuticals announced Wednesday the signing of an exclusive licence agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). According to a company statement, Nimoral is a hypoxic radiosensitiser to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programmes throughout the world. Under the terms of the agreement, Hikma will have the exclusive rights to register, manufacture, distribute and market Nimoral in 20 markets in the MENA region including Turkey, leveraging Hikma’s strong local presence and regulatory expertise, with over 1,800 sales and marketing reps across the region.